Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 14 hours ago
Genomics inks partnership deal with Greywolf to assess gene datasets
about 14 hours ago
Genomics inked a partnership deal with fellow U.K.-based biotech Greywolf Therapeutics to...
‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO
about 14 hours ago
"We want to develop those programs as far as we can ourselves,”...
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
about 16 hours ago
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has...
CBER chief Prasad steps aside, deputy takes the reins as search for successor continues
about 17 hours ago
Katherine Szarama, Ph.D., will take over as CBER director in an acting...
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
about 18 hours ago
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing...
Ligand tries to disembark from part of Viking pact, alleging contract breach
about 18 hours ago
Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with...
Chutes & Ladders—Astellas appoints new top strategist from Sanofi Japan
about 18 hours ago
After last month’s departure of longtime executive Adam Pearson, Astellas has picked...
Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
1 day ago
Amgen has pulled the plug on midstage drug candidates for cancer and...
Scaling theranostics through access, safety and trust
1 day ago
Curium’s Mike Patterson on improving access, safety and trust to scale theranostics...
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
1 day ago
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's...
CareDx expands into cancer testing with $260M Naveris buy
1 day ago
Transplant-focused precision medicine company CareDx is making a move into the oncology...
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
1 day ago
Indivior ended internal development of an opioid use disorder candidate after a...